Centiva Capital, LP Revance Therapeutics, Inc. Transaction History
Centiva Capital, LP
- $4.79 Billion
- Q3 2024
A detailed history of Centiva Capital, LP transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Centiva Capital, LP holds 50,000 shares of RVNC stock, worth $128,499. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,000
Previous 141,259
64.6%
Holding current value
$128,499
Previous $363,000
64.74%
% of portfolio
0.0%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding RVNC
# of Institutions
226Shares Held
82.9MCall Options Held
680KPut Options Held
896K-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.73MShares$14.7 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA4.78MShares$12.3 Million0.0% of portfolio
-
Fil LTD Hamilton, D04.19MShares$10.8 Million0.01% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ4.16MShares$10.7 Million0.49% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...